Charles River, Insightec team on therapy in neuroscience with FUS

Charles River Laboratories International and Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care announced the launch of a five-year strategic collaboration to provide Charles River’s clients access to a comprehensive global service and technology platform for the application of focused ultrasound FUS for drug discovery and preclinical development of therapeutics in neuroscience. Insightec’s novel low-frequency ultrasound platform non-invasively disrupts the blood-brain barrier, enabling drugs to be delivered to targeted brain areas. The procedure has generated positive clinical evidence across several neurological diseases, including Parkinson’s disease, Alzheimer’s disease..”This partnership will not only expand the application of our low-frequency focused ultrasound technology, but also accelerate the development of groundbreaking therapies for neurological conditions,” said Arjun Desai, M.D., Chief Strategic Innovation Officer of Insightec. “By combining our expertise, we aim to revolutionize the way next generation therapeutics are delivered and actuated in the brain, ultimately improving the lives of millions globally.”